Valuation: Camurus AB

Market Cap 3.62TCr 360.53Cr 320.33Cr 298.98Cr 272.51Cr 513.95Cr 35TCr 518.73Cr 1.4TCr 18TCr 1.35TCr 1.32TCr 57TCr P/E 2026 *
37.1x
P/E 2027 * 26.4x
Enterprise Value 3.17TCr 315.52Cr 280.34Cr 261.65Cr 238.49Cr 449.78Cr 30TCr 453.97Cr 1.23TCr 16TCr 1.18TCr 1.16TCr 50TCr EV / Sales 2026 *
11.1x
EV / Sales 2027 * 8.1x
Free-Float
66.89%
Yield 2026 *
-
Yield 2027 * -
1 day-3.89%
3 months+1.21%
6 months+12.27%
Current year-8.01%
Current year 54
Extreme 54
71
1 year 54
Extreme 54
71
3 years 46.15
Extreme 46.15
71.07
5 years 21.81
Extreme 21.81
71.07
10 years 7.48
Extreme 7.48
71.07
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2003
Director of Finance/CFO 57 01/07/2025
Chief Tech/Sci/R&D Officer 58 01/01/2025
Director TitleAgeSince
Director/Board Member 63 01/01/2002
Chairman 77 01/01/2015
Director/Board Member 61 07/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.89%-.--% - - 360.53Cr
-0.61%-3.43%+36.07%+117.61% 1,01900Cr
-1.02%-5.60%+35.72%+64.82% 62TCr
+1.11%-0.58%+12.36%+78.27% 46TCr
+0.34%-3.01%+61.79%+41.79% 36TCr
-0.95%-4.05%+20.54%+40.33% 33TCr
-1.46%-2.89%+10.57%+26.54% 27TCr
-1.35%-5.43%-6.17%+8.82% 24TCr
-1.04%-2.79%+35.30%+54.42% 22TCr
-1.87%-4.10%+28.44%+97.54% 18TCr
Average -1.07%-3.39%+26.07%+58.90% 41.08TCr
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2026 *2027 *
Net sales 285.66Cr 28Cr 25Cr 24Cr 22Cr 41Cr 2.74TCr 41Cr 110.69Cr 1.4TCr 106.87Cr 104.55Cr 4.49TCr 374.78Cr 37Cr 33Cr 31Cr 28Cr 53Cr 3.59TCr 54Cr 145.23Cr 1.84TCr 140.21Cr 137.17Cr 5.89TCr
Net income 98Cr 9.74Cr 8.66Cr 8.08Cr 7.36Cr 14Cr 936.59Cr 14Cr 38Cr 478.8Cr 37Cr 36Cr 1.54TCr 137.19Cr 14Cr 12Cr 11Cr 10Cr 19Cr 1.31TCr 20Cr 53Cr 671.83Cr 51Cr 50Cr 2.16TCr
Net Debt -451.72Cr -45Cr -40Cr -37Cr -34Cr -64Cr -4.33TCr -65Cr -175.04Cr -2.21TCr -168.99Cr -165.33Cr -7.1TCr -580.71Cr -58Cr -51Cr -48Cr -44Cr -82Cr -5.56TCr -83Cr -225.03Cr -2.84TCr -217.25Cr -212.54Cr -9.13TCr
Logo Camurus AB
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Employees
316
Date Price Change Volume
30/26/30 $0.000000 - 16
28/26/28 $0.000000 - 30
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
608.00SEK
Average target price
793.00SEK
Spread / Average Target
+30.43%

Quarterly revenue - Rate of surprise